X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5528) 5528
Book Chapter (244) 244
Dissertation (45) 45
Publication (11) 11
Conference Proceeding (8) 8
Magazine Article (6) 6
Book / eBook (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3523) 3523
life sciences & biomedicine (3326) 3326
nonalcoholic steatohepatitis (2407) 2407
humans (2301) 2301
non-alcoholic steatohepatitis (1749) 1749
male (1666) 1666
gastroenterology & hepatology (1509) 1509
non-alcoholic fatty liver disease (1317) 1317
steatohepatitis (1287) 1287
fatty liver (1270) 1270
animals (1233) 1233
female (1167) 1167
liver (1135) 1135
liver diseases (1093) 1093
nonalcoholic fatty liver disease (1026) 1026
insulin resistance (931) 931
liver - pathology (908) 908
obesity (894) 894
middle aged (872) 872
fibrosis (854) 854
adult (799) 799
steatosis (798) 798
fatty liver - pathology (677) 677
liver - metabolism (628) 628
inflammation (624) 624
risk factors (617) 617
mice (616) 616
digestive system diseases (597) 597
metabolic syndrome (589) 589
nutritional and metabolic diseases (532) 532
oxidative stress (495) 495
gastroenterology and hepatology (489) 489
biopsy (483) 483
cirrhosis (462) 462
digestive system (447) 447
fatty liver - metabolism (446) 446
analysis (443) 443
hepatocellular carcinoma (440) 440
liver cirrhosis (439) 439
diabetes (429) 429
non-alcoholic fatty liver disease - pathology (418) 418
hepatology (405) 405
disease models, animal (403) 403
aged (393) 393
diet (381) 381
disease progression (371) 371
medicine (364) 364
rodents (362) 362
mice, inbred c57bl (354) 354
medicine & public health (351) 351
nash (335) 335
fatty liver - etiology (332) 332
biochemistry & molecular biology (329) 329
pharmacology & pharmacy (324) 324
non-alcoholic fatty liver disease - metabolism (323) 323
lipids (318) 318
non‐alcoholic steatohepatitis (316) 316
hepatitis (306) 306
fatty acids (305) 305
liver - drug effects (303) 303
nafld (292) 292
review (290) 290
fatty liver - complications (286) 286
liver cirrhosis - pathology (286) 286
metabolism (286) 286
body mass index (281) 281
rats (277) 277
gene expression (273) 273
gastroenterology (263) 263
oncology (259) 259
endocrinology & metabolism (257) 257
fatty liver - diagnosis (255) 255
health aspects (250) 250
severity of illness index (250) 250
research article (247) 247
development and progression (238) 238
care and treatment (237) 237
surgery (235) 235
liver fibrosis (234) 234
physiological aspects (234) 234
lipid metabolism (232) 232
non-alcoholic fatty liver disease - drug therapy (228) 228
prevalence (228) 228
pathology (227) 227
cholesterol (225) 225
medicine, research & experimental (220) 220
abridged index medicus (216) 216
research & experimental medicine (216) 216
insulin (215) 215
biology (213) 213
type 2 diabetes (213) 213
apoptosis (212) 212
obesity - complications (212) 212
biomarkers - blood (211) 211
non-alcoholic fatty liver disease - complications (211) 211
research (209) 209
alanine transaminase - blood (207) 207
fatty liver - epidemiology (206) 206
liver cancer (206) 206
original (206) 206
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5470) 5470
Korean (99) 99
Japanese (89) 89
German (61) 61
Spanish (58) 58
Russian (54) 54
Portuguese (44) 44
French (28) 28
Czech (10) 10
Chinese (9) 9
Polish (9) 9
Hungarian (8) 8
Turkish (7) 7
Italian (6) 6
Persian (4) 4
Ukrainian (4) 4
Bosnian (1) 1
Croatian (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver international, ISSN 1478-3223, 01/2017, Volume 37, Issue S1, pp. 97 - 103
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic... 
non‐alcoholic steatohepatitis (NASH) | peroxisome proliferator‐activator receptor (PPAR) agonists | farnesoid X receptor (FXR) | non‐alcoholic fatty liver disease (NAFLD) | ROS (reactive oxygen species) | glucagon‐like peptide (GLP‐1) agonist | non-alcoholic fatty liver disease (NAFLD) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | non-alcoholic steatohepatitis (NASH) | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Index Medicus | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 04/2016, Volume 63, Issue 4, pp. 1190 - 1204
Journal Article